Physician profile
Peter Howard
NPI 1952357543
$2,714.09
in general payments reported to CMS, 2019-2025
33 companies · $532 in 2025
The $532 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $181 · 2021: $364 · 2022: $131 · 2023: $109 · 2024: $353 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.47 | 2019-2025 | |
| Astellas Pharma US INC | $238.94 | 2019-2025 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $195.88 | 2024-2025 | Gemtesa, Orgovyx |
| Medtronic USA, INC. | $182.79 | 2019 | |
| Allergan, INC. | $165.13 | 2019-2021 | |
| Procept Biorobotics Corporation | $142.49 | 2024 | Aquabeam System |
| Dendreon Pharmaceuticals LLC | $113.94 | 2019-2024 | Provenge |
| 180 Medical, INC. | $107.46 | 2019-2025 | |
| Pfizer INC. | $103.38 | 2019-2025 | |
| Coloplast Corp | $91.49 | 2019-2024 | |
| Immunitybio, INC. | $90.53 | 2025 | |
| Janssen Biotech, INC. | $73.98 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $73.77 | 2019-2020 | |
| Boston Scientific Corporation | $52.56 | 2019-2024 | Ams 700 |
| Dentsply Ih Ab | $44.46 | 2024 | Lofric |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Metuchen Pharmaceuticals | $40.54 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $40.33 | 2019-2024 | Adstiladrin |
| Blue Earth Diagnostics | $39.71 | 2019 | |
| Axonics, INC. | $33.83 | 2021 | |
| Tolmar, INC. | $33.80 | 2025 | Eligard |
| Myovant Sciences INC. | $27.60 | 2021 | |
| Calyxo, INC. | $26.77 | 2025 | Cvac Aspiration System |
| Aytu Biopharma, INC. | $26.04 | 2019-2020 | |
| Olympus America INC. | $22.64 | 2025 | Soltive |
| Bioprotect Medical, INC. | $20.92 | 2025 | Bioprotect Balloon Implant System |
| Photocure INC | $19.80 | 2025 | Cysview |
| Novartis Pharmaceuticals Corporation | $18.08 | 2025 | |
| Antares Pharma, INC. | $15.99 | 2024 | Xyosted |
| Telix Pharmaceuticals | $15.85 | 2025 | Illuccix |
| Urovant Sciences INC | $14.99 | 2021 | |
| Urogen Pharma, INC. | $14.48 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $12.78 | 2019 | |
| Endo Pharmaceuticals INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.